CHEK2 germline mutations are associated with an increased risk of breast cancer (BC) with an odds ratio of approximately 1.5–3.0 and an absolute risk of up to 37% for developing a BC by the age of 70 years (1–7). Here, CHEK2 is linked to breast carcinoma.